发明名称 |
Interleukin-4 and Interleukin-1beta synergistically induce VCAM-1 |
摘要 |
<p>A therapeutic method of modulating the immune response, by administering to a patient an amount of IL-4 effective to promote peripheral blood lymphocyte adhesion to microvascular endothelial cells in lymphoid organs. The IL-4 is preferably co-administered with IL-1 beta . An improved method of screening a cell line for the production of a binding partner that binds with a cell adhesion molecule by contacting the binding partner with IL4-activated and non-activated microvascular endothelial cells, and selecting binding partners that bind to the IL-4 activated microvascular endothelial cells but not to the non-activated microvascular endothelial cells. The selected binding partners may thereafter be tested for the ability to block lymphocyte binding to cytokine-activated endothelial cells. The binding partners are preferably also characterized by binding to human VCAM-1 and to IL4- or TNF alpha -activated bone marrow stromal cells. A representative embodiment is mAb 6G10 produced by hybridoma ATTC No. HB 10519. A therapeutic method of modulating the immune response in a patient, by administering to the patient an agent that specifically binds to IL4-activated microvascular endothelial cells, in an amount effective to impede transmigration of lymphocytes that specifically bind to VCAM-1 from blood across postcapillary venules.</p> |
申请公布号 |
EP0745611(A1) |
申请公布日期 |
1996.12.04 |
申请号 |
EP19960202257 |
申请日期 |
1991.08.01 |
申请人 |
FRED HUTCHINSON CANCER RESEARCH CENTER |
发明人 |
MASINOVSKY, BORIS;GALLATIN, WILLIAM M.;SIMMONS, PAUL J. |
分类号 |
A61K38/00;A61K38/20;A61K45/00;A61P37/00;C07K14/705;C07K16/28;(IPC1-7):C07K16/28;A61K39/395;C12N5/20 |
主分类号 |
A61K38/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|